RT Journal Article
SR Electronic
T1 Comparative dynamic aerosol efficiencies of three emergent coronaviruses and the unusual persistence of SARS-CoV-2 in aerosol suspensions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.13.20063784
DO 10.1101/2020.04.13.20063784
A1 A.C. Fears
A1 W.B. Klimstra
A1 P. Duprex
A1 A. Hartman
A1 S.C. Weaver
A1 K.C. Plante
A1 D. Mirchandani
A1 J.A. Plante
A1 P.V. Aguilar
A1 D. Fernández
A1 A. Nalca
A1 A. Totura
A1 D. Dyer
A1 B. Kearney
A1 M. Lackemeyer
A1 J.K. Bohannon
A1 R. Johnson
A1 R.F. Garry
A1 D.S. Reed
A1 C.J. Roy
YR 2020
UL http://medrxiv.org/content/early/2020/04/18/2020.04.13.20063784.abstract
AB The emergent coronavirus, designated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a zoonotic pathogen that has demonstrated remarkable transmissibility in the human population and is the etiological agent of a current global pandemic called COVID-191. We measured the dynamic (short-term) aerosol efficiencies of SARS-CoV-2 and compared the efficiencies with two other emerging coronaviruses, SARS-CoV (emerged in 2002) and Middle Eastern respiratory syndrome CoV (MERS-CoV; emerged starting in 2012). We also quantified the long-term persistence of SARS-CoV-2 and its ability to maintain infectivity when suspended in aerosols for up to 16 hours.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and the the Office of the Chancellor at the University of Pittsburgh. Work performed at Tulane National Primate Research Center (CJR, ACF) was supported in part by the National Institutes of Health grant P51OD011104. RFG was supported by the National Institutes of Health grant number U19AI135995. UTMB work was supported by NIH grant R24AI120942. The Defense Health Program provided the funding for SARS-CoV-2 work in USAMRIID. The work at NIH-IRF was funded in part through the NIAID, Division of Intramural Research and Division of Clinical Research, Battelle Memorial Institute’s prime contract with NIAID under HHSN272200700016I and in whole or in part with Federal funds from the NIAID, NIH, DHHS, HHSN272201800013C. JKB performed this work as an employee of Battelle Memorial Institute. MGL performed this work as an employee of Lovelace Respiratory Research Institute and Laulima Government Solutions, LLC.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data can be made available for review upon request.